Form 4: Astrana Health CMO Sells Shares for Tax Obligations

Astrana Health's Chief Medical Officer, Dinesh M. Kumar, disposed of 1,694 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Dinesh M. Kumar, Chief Medical Officer of Astrana Health, Inc. (ASTH), reported a transaction on September 5, 2025.
• The transaction involved the disposition of 1,694 shares of common stock, executed under a Rule 10b5-1(c) plan.
• These shares were surrendered to satisfy tax withholding obligations upon the vesting of restricted stock units.
• The price per share for the disposition was $29.7.
• Following this transaction, Kumar beneficially owns 217,893 shares of common stock.
• This beneficial ownership includes various restricted stock and restricted stock units with future vesting dates and performance conditions, as well as 1,405 shares acquired under the Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary tax-related sale, which is neutral in sentiment. The continued significant beneficial ownership, including substantial unvested equity, suggests ongoing alignment with shareholder interests.

Positives

• The transaction is a routine tax-related disposition, not a discretionary sale, indicating no change in investment sentiment.
• The reporting person continues to hold a substantial number of shares (217,893), including significant unvested equity, aligning interests with shareholders.

Negatives

• A reduction in direct share ownership, albeit for tax purposes.

Risks

• Future vesting of restricted stock and restricted stock units is subject to continuous employment and, for some grants, achievement of certain performance goals, which could impact the ultimate number of shares received.

Future Outlook

The filing details future vesting schedules for a significant portion of the Chief Medical Officer's equity compensation, including restricted stock and restricted stock units, some of which are contingent on performance goals and continuous employment through 2026 and beyond.

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, common across all industries for executives receiving stock-based awards. It does not provide specific insights into Astrana Health's operational performance or broader industry trends.

Comparison to Industry Standards

• This is a standard Form 4 filing for an executive's tax-related share disposition, executed under a Rule 10b5-1(c) plan. Such transactions are common for executives in publicly traded companies across various sectors, including healthcare, when restricted stock or restricted stock units vest.
• Similar tax-related sales are frequently observed at companies like UnitedHealth Group (UNH) or CVS Health (CVS) when their executives' equity awards vest.
• The volume of shares disposed (1,694) is relatively small compared to the total beneficial ownership (217,893 shares), which is typical for tax-related transactions designed to cover statutory withholding requirements rather than a full liquidation of holdings.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related transaction, not a discretionary sale indicating a change in confidence. The executive retains significant equity, aligning interests.
• Employees: No direct impact on general employees.

Next Steps

• Monitoring future vesting events for the remaining restricted stock and restricted stock units held by the Chief Medical Officer.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the Chief Medical Officer to cover tax obligations upon the vesting of restricted stock units, executed under a Rule 10b5-1(c) plan. Such transactions are common and do not typically signal a change in the executive's confidence in the company or its future prospects. The executive retains a substantial beneficial ownership, including significant unvested equity, which aligns their interests with long-term shareholder value. Therefore, based solely on this filing, there is no new information to warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Astrana Health, ASTH, Dinesh M. Kumar, Chief Medical Officer, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation, 10b5-1 Plan